Talis Biomedical Corporation
TLIS
$1.60
-$0.08-4.76%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 40.54% | 41.50% | 45.13% | 34.22% | 32.50% |
| Total Depreciation and Amortization | -90.11% | -90.07% | -91.28% | -33.59% | 211.79% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 0.71% | 31.35% | -2.65% | 69.87% | 37.12% |
| Change in Net Operating Assets | -387.16% | -149.91% | 55.45% | 100.85% | 98.84% |
| Cash from Operations | 38.16% | 40.69% | 46.83% | 56.47% | 64.08% |
| Capital Expenditure | 101.62% | 59.19% | 69.91% | 75.40% | 42.17% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 109.66% | 61.84% | 69.91% | 75.40% | 42.17% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -98.40% | -98.40% | -91.87% | -96.93% | -93.71% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -98.40% | -98.40% | -91.87% | -96.93% | -93.71% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 39.58% | 40.92% | 47.02% | 56.51% | 63.46% |
